Abstract:Extraocular muscle weakness occurs in most of the myasthenia gravis (MG) patients and it is often the initial complaint. Approximately 10–20% of MG patients with extraocular muscle weakness display only ocular symptoms and rest of the patients subsequently develop generalized muscle weakness. It is not entirely clear why some MG patients develop only ocular symptoms and why extraocular muscle weakness almost always precedes generalized muscle weakness. These facts are often explained by increased susceptibility of extraocular muscles due to their reduced endplate safety factor and lower complement inhibitor expression. Findings of a recently developed animal model of ocular MG suggest that additional factors might be in play. While immunization of HLA transgenic and wild-type (WT) mice with the native acetylcholine receptor (AChR) pentamer carrying conformational epitopes generates severe generalized muscle weakness, immunization of the same mouse strains with recombinant unfolded AChR subunits containing linear epitopes induces ptosis with or without mild generalized muscle weakness. Notably, immunization of mice with deficient T helper cell-mediated antigen presentation with recombinant AChR subunits or whole native AChR pentamer also induces ocular symptoms, AChR-reactive B cells and AChR antibodies. Based on these findings, we hypothesize that ocular symptoms observed in the earlier stages of MG might be triggered by linear and non-conformational AChR epitopes expressed by thymic cells or invading microorganisms. This initial AChR autoimmunity might be managed by T cell-independent and B cell mediated mechanisms yielding low affinity AChR antibodies. These antibodies are putatively capable of inducing muscle weakness only in extraocular muscles which have increased vulnerability due to their inherent biological properties. After this initial attack, as AChR bearing immune complexes form and the immune system gains access to the native AChR expressed by muscle and thymic myoid cells, a more robust anti-AChR autoimmunity develops giving way to high affinity AChR antibodies, thymic germinal center formation and severe generalized muscle weakness. Accurate characterization of chain if events leading to ocular and generalized symptoms in MG might enable development of novel therapeutics that might prevent the transition from mild ocular symptoms to severe generalized weakness in earlier stages of the disease.

Susceptible Mechanisms of Extraocular Muscles in the Passive Transferred Experimental Myasthenia Gravis Rats

The Involving Proofs of Extraocular Muscle in Passive Transferred Experimental Myasthenia Gravis in Rats

Extraocular Muscle Characteristics Related To Myasthenia Gravis Susceptibility

Non-neuronal cholinergic activity is potentiated in myasthenia gravis

Model of Passive Transferred Experimental Myasthenia Gravis Inducing on Sprague-Dawley Rats

Establishment of a Mouse Model of Experimental Autoimmune Myasthenia Gravis

Pathogenesis of Myasthenia Gravis in Transgenic Mouse Induced with Torpedo Acetylcholine Receptor

Induce Experimental Autoimmune Myasthenia Gravis on Rats by Passive Transfer Acetylcholine Receptor Monoclonal Antibody

Muscle-selective synaptic disassembly and reorganization in MuSK antibody positive MG mice.

The mouse passive‐transfer model of MuSK myasthenia gravis: disrupted MuSK signaling causes synapse failure

Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis

Influence of Injection of Chinese Botulinum Toxin Type A on the Histomorphology and Myosin Heavy Chain Composition of Rat Gastrocnemius Muscles.

Institution of Model of Myasthenia Gravis in Transgenic Mice

A Study of Magnetic Motor Evoked Potentials in the Central Nervous System Dysfunction Model of Myasthenia Gravis

Ocular Myasthenia Gravis Induced By Human Acetylcholine Receptor Epsilon Subunit Immunization In Hla Dr3 Transgenic Mice

Anti-presynaptic membrane receptor antibodies in myasthenia gravis.

A new mouse model of autoimmune ocular myasthenia gravis.

Ocular And Generalized Myasthenia Gravis Induced By Human Acetylcholine Receptor ? Subunit Immunization

Are linear AChR epitopes the real culprit in ocular myasthenia gravis

Titin antibody in myasthenia gravis and its clinical significance

Acute severe animal model of anti-muscle-specific kinase myasthenia: combined postsynaptic and presynaptic changes